Hereditary Angioedema Management: Individualization

Published:November 01, 2021DOI:https://doi.org/10.1016/j.nurpra.2021.09.016

      Highlights

      • The key aim of hereditary angioedema (HAE) management is to improve quality of life.
      • HAE management plans are individualized to patients’ lifestyles and preferences.
      • Shared decision making is used to facilitate individualization of HAE management.
      • Nurse practitioners are key to successful treatment individualization in HAE.

      Abstract

      Hereditary angioedema (HAE) is a chronic, incurable disease characterized by recurrent, unpredictable episodes of swelling in various parts of the body. The presentation of HAE is highly variable, and multiple treatment options are available for disease control and prophylaxis. HAE management plans should therefore be individualized to reduce mortality and morbidity in a way that prioritizes quality of life based on each patient’s lifestyle, preferences, and goals. This report discusses the key considerations in HAE management and patient-centered care, including the use of shared decision making and the vital roles performed by nurse practitioners and other health care providers.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to The Journal for Nurse Practitioners
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Longhurst H.J.
        • Bork K.
        Hereditary angioedema: an update on causes, manifestations and treatment.
        Br J Hosp Med (Lond). 2019; 80: 391-398https://doi.org/10.12968/hmed.2019.80.7.391
        • Banday A.Z.
        • Kaur A.
        • Jindal A.K.
        • et al.
        An update on the genetics and pathogenesis of hereditary angioedema.
        Genes Dis. 2020; 7: 75-83https://doi.org/10.1016/j.gendis.2019.07.002
        • Bork K.
        Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor.
        Allergy Asthma Clin Immunol. 2010; 6: 15https://doi.org/10.1186/1710-1492-6-15
        • Cichon S.
        • Martin L.
        • Hennies H.C.
        • et al.
        Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III.
        Am J Hum Genet. 2006; 79: 1098-1104https://doi.org/10.1086/509899
        • Busse P.J.
        • Christiansen S.C.
        • Riedl M.A.
        • et al.
        US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema.
        J Allergy Clin Immunol Pract. 2020; 9: 132-150https://doi.org/10.1016/j.jaip.2020.08.046
        • Lumry W.R.
        • Settipane R.A.
        Hereditary angioedema: epidemiology and burden of disease.
        Allergy Asthma Proc. 2020; 41: S8-S13https://doi.org/10.2500/aap.2020.41.200050
        • Nzeako U.C.
        • Frigas E.
        • Tremaine W.J.
        Hereditary angioedema: a broad review for clinicians.
        Arch Intern Med. 2001; 161: 2417-2429https://doi.org/10.1001/archinte.161.20.2417
        • Pappalardo E.
        • Cicardi M.
        • Duponchel C.
        • et al.
        Frequent de novo mutations and exon deletions in the C1 inhibitor gene of patients with angioedema.
        J Allergy Clin Immunol. 2000; 106: 1147-1154https://doi.org/10.1067/mai.2000.110471
        • Bork K.
        • Meng G.
        • Staubach P.
        • Hardt J.
        Hereditary angioedema: new findings concerning symptoms, affected organs, and course.
        Am J Med. 2006; 119: 267-274https://doi.org/10.1016/j.amjmed.2005.09.064
        • Bouillet L.
        Hereditary angioedema in women.
        Allergy Asthma Clin Immunol. 2010; 6: 17https://doi.org/10.1186/1710-1492-6-17
        • Caballero T.
        • Maurer M.
        • Longhurst H.J.
        • et al.
        Triggers and prodromal symptoms of angioedema attacks in patients with hereditary angioedema.
        J Investig Allergol Clin Immunol. 2016; 26: 383-386https://doi.org/10.18176/jiaci.0102
        • Rubinstein E.
        • Stolz L.E.
        • Sheffer A.L.
        • et al.
        Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency.
        BMC Gastroenterol. 2014; 14: 71https://doi.org/10.1186/1471-230X-14-71
        • Bork K.
        • Hardt J.
        • Witzke G.
        Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency.
        J Allergy Clin Immunol. 2012; 130: 692-697https://doi.org/10.1016/j.jaci.2012.05.055
        • Lumry W.R.
        • Castaldo A.J.
        • Vernon M.K.
        • et al.
        The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression.
        Allergy Asthma Proc. 2010; 31: 407-414https://doi.org/10.2500/aap.2010.31.3394
      1. Devercelli G, Davis KH, Brown M, et al. Patient-reported burden of hereditary angioedema: findings from a US patient survey. Oral presentation at American Academy of Allergy, Asthma and Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress, Orlando, FL, March 2-5, 2018.

        • Wilson D.A.
        • Bork K.
        • Shea E.P.
        • et al.
        Economic costs associated with acute attacks and long-term management of hereditary angioedema.
        Ann Allergy Asthma Immunol. 2010; 104: 314-320https://doi.org/10.1016/j.anai.2010.01.024
        • Lumry W.R.
        Hereditary angioedema: the economics of treatment of an orphan disease.
        Front Med (Lausanne). 2018; 5: 22https://doi.org/10.3389/fmed.2018.00022
        • Maurer M.
        • Magerl M.
        • Ansotegui I.
        • et al.
        The International WAO/EAACI Guideline for the Management of Hereditary Angioedema—the 2017 revision and update.
        Allergy. 2018; 73: 1575-1596https://doi.org/10.1111/all.13384
        • Farkas H.
        • Zotter Z.
        • Csuka D.
        • et al.
        Short-term prophylaxis in hereditary angioedema due to deficiency of the C1-inhibitor—a long-term survey.
        Allergy. 2012; 67: 1586-1593https://doi.org/10.1111/all.12032
        • BioCryst Pharmaceuticals Inc
        ORLADEYO™ (berotralstat) capsules, for oral use. Prescribing information. December 2020.
        (Accessed June 30, 2021)
        • Betschel S.
        • Badiou J.
        • Binkley K.
        • et al.
        The International/Canadian Hereditary Angioedema Guideline.
        Allergy Asthma Clin Immunol. 2019; 15: 72https://doi.org/10.1186/s13223-019-0376-8
        • Banerji A.
        • Riedl M.A.
        • Bernstein J.A.
        • et al.
        Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial.
        JAMA. 2018; 320: 2108-2121https://doi.org/10.1001/jama.2018.16773
        • Longhurst H.
        • Cicardi M.
        • Craig T.
        • et al.
        Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor.
        N Engl J Med. 2017; 376: 1131-1140https://doi.org/10.1056/NEJMoa1613627
        • Radojicic C.
        • Riedl M.A.
        • Craig T.J.
        • et al.
        Patient perspectives on the treatment burden of injectable medication for hereditary angioedema.
        Allergy Asthma Proc. 2021; 42: S4-S10https://doi.org/10.2500/aap.2021.42.210025
        • Craig T.
        • Busse P.
        • Gower R.G.
        • et al.
        Long-term prophylaxis therapy in patients with hereditary angioedema with C1 inhibitor deficiency.
        Ann Allergy Asthma Immunol. 2018; 121: 673-679https://doi.org/10.1016/j.anai.2018.07.025
        • Shapiro R.S.
        • Zacek L.
        Training hereditary angioedema patients to self-administer intravenous C1 esterase inhibitor concentrate.
        J Infus Nurs. 2014; 37: 284-290https://doi.org/10.1097/NAN.0000000000000049
        • Zanichelli A.
        • Farkas H.
        • Bouillet L.
        • et al.
        The global registry for hereditary angioedema due to C1-inhibitor deficiency.
        Clin Rev Allergy Immunol. 2021; 61: 77-83https://doi.org/10.1007/s12016-021-08855-4
        • Bygum A.
        • Aygoren-Pursun E.
        • Beusterien K.
        • et al.
        Burden of illness in hereditary angioedema: a conceptual model.
        Acta Derm Venereol. 2015; 95: 706-710https://doi.org/10.2340/00015555-2014
        • Lumry W.
        • Templeton T.
        • Omert L.
        • Levy D.
        Advances in hereditary angioedema: the prevention of angioedema attacks with subcutaneous C1-inhibitor replacement therapy.
        J Infus Nurs. 2020; 43: 134-145https://doi.org/10.1097/NAN.0000000000000365
        • Chiao J.
        • Craig T.
        • Feuersenger H.
        Weight-based dosing of subcutaneous C1-inhibitor facilitates management of hereditary angioedema in obese patients.
        J Allergy Clin Immunol. 2020; 145: AB106https://doi.org/10.1016/j.jaci.2019.12.634
        • Bernstein J.A.
        • Riedl M.
        • Zacek L.
        • Shapiro R.S.
        Facilitating home-based treatment of hereditary angioedema.
        Allergy Asthma Proc. 2015; 36: 92-99https://doi.org/10.2500/aap.2015.36.3820
        • Geba D.
        • Mohd Sani J.
        • Gascon M.
        • et al.
        Hereditary angioedema patients would prefer newer-generation oral prophylaxis.
        J Drug Assess. 2021; 10: 51-56https://doi.org/10.1080/21556660.2020.1863699
        • Andrade J.G.
        • Krahn A.D.
        • Skanes A.C.
        • et al.
        Values and preferences of physicians and patients with nonvalvular atrial fibrillation who receive oral anticoagulation therapy for stroke prevention.
        Can J Cardiol. 2016; 32: 747-753https://doi.org/10.1016/j.cjca.2015.09.023
        • Granero-Molina J.
        • Sanchez-Hernandez F.
        • Fernandez-Sola C.
        • et al.
        The diagnosis of hereditary angioedema: family caregivers’ experiences.
        Clin Nurs Res. 2020; 29: 117-126https://doi.org/10.1177/1054773818780102
        • Banerji A.
        • Davis K.H.
        • Brown T.M.
        • et al.
        Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States.
        Ann Allergy Asthma Immunol. 2020; 124: 600-607https://doi.org/10.1016/j.anai.2020.02.018
        • Bernstein J.A.
        • Tyson C.
        • Relan A.
        • et al.
        Modeling cost-effectiveness of on-demand treatment for hereditary angioedema attacks.
        J Manag Care Spec Pharm. 2020; 26: 203-210https://doi.org/10.18553/jmcp.2019.19217
        • Vande Walle S.E.
        • Starner C.I.
        • Gleason P.P.
        Hereditary Angioedema: A Comprehensive Integrated Medical and Pharmacy Claims Analysis of Utilization and Costs Among 15 Million Commercially Insured Members. April 2018.
        (Accessed June 30, 2021)
        • Banerji A.
        • Anderson J.
        • Johnston D.T.
        Optimal management of hereditary angioedema: shared decision-making.
        J Asthma Allergy. 2021; 14: 119-125https://doi.org/10.2147/JAA.S284029
        • Settipane R.A.
        • Bukstein D.A.
        • Riedl M.A.
        Hereditary angioedema and shared decision making.
        Allergy Asthma Proc. 2020; 41: S55-S60https://doi.org/10.2500/aap.2020.41.200057
        • Elwyn G.
        • Frosch D.
        • Thomson R.
        • et al.
        Shared decision making: a model for clinical practice.
        J Gen Intern Med. 2012; 27: 1361-1367https://doi.org/10.1007/s11606-012-2077-6
        • Blaiss M.S.
        • Steven G.C.
        • Bender B.
        • et al.
        Shared decision making for the allergist.
        Ann Allergy Asthma Immunol. 2019; 122: 463-470https://doi.org/10.1016/j.anai.2018.08.019
        • Stacey D.
        • Légaré F.
        • Lewis K.
        • et al.
        Decision aids for people facing health treatment or screening decisions.
        Cochrane Database Syst Rev. 2017; 4: CD001431https://doi.org/10.1002/14651858.CD001431.pub5
        • Robinson A.
        • Thomson R.
        Variability in patient preferences for participating in medical decision making: implication for the use of decision support tools.
        Qual Health Care. 2001; 10: i34-i38https://doi.org/10.1136/qhc.0100034
        • HealthIT.gov National Learning Consortium
        Fact sheet: Shared Decision Making. December 2013.
        (Accessed June 30, 2021)
        • Raue P.J.
        • Schulberg H.C.
        • Lewis-Fernandez R.
        • et al.
        Shared decision-making in the primary care treatment of late-life major depression: a needed new intervention?.
        Int J Geriatr Psychiatry. 2010; 25: 1101-1111https://doi.org/10.1002/gps.2444
        • Muller N.
        Revitalizing the Health Belief Model in support of shared decision-making.
        Ostomy Wound Manage. 2012; 58 (12,14)
        • Dempster J.
        Management of hereditary angioedema.
        Nurs Stand. 2013; 27: 35-40https://doi.org/10.7748/ns2013.05.27.37.35.e7336
        • de Thurah A.
        • Esbensen B.A.
        • Roelsgaard I.K.
        • et al.
        Efficacy of embedded nurse-led versus conventional physician-led follow-up in rheumatoid arthritis: a systematic review and meta-analysis.
        RMD Open. 2017; 3e000481https://doi.org/10.1136/rmdopen-2017-000481
        • Kuethe M.C.
        • Vaessen-Verberne A.A.
        • Elbers R.G.
        • Van Aalderen W.M.
        Nurse versus physician-led care for the management of asthma.
        Cochrane Database Syst Rev. 2013; 28: CD009296https://doi.org/10.1002/14651858.CD009296.pub2
        • Burton J.
        • Murphy E.
        • Riley P.
        Primary immunodeficiency disease: a model for case management of chronic diseases.
        Prof Case Manag. 2010; 15: 5-14https://doi.org/10.1097/NCM.0b013e3181b5dec4
        • Crowe M.
        • Jones V.
        • Stone M.A.
        • Coe G.
        The clinical effectiveness of nursing models of diabetes care: a synthesis of the evidence.
        Int J Nurs Stud. 2019; 93: 119-128https://doi.org/10.1016/j.ijnurstu.2019.03.004
        • Longhurst H.J.
        • Farkas H.
        • Craig T.
        • et al.
        HAE international home therapy consensus document.
        Allergy Asthma Clin Immunol. 2010; 6: 22https://doi.org/10.1186/1710-1492-6-22
        • Federizo A.
        • Shullick M.
        • Witkop M.
        The viability and necessity of APRN-led care models in the clinical management of haemophilia and other inherited bleeding and clotting disorders.
        Haemophilia. 2018; 24: 563-569https://doi.org/10.1111/hae.13536
        • Murphy E.
        • Donahue C.
        • Omert L.
        • et al.
        Training patients for self-administration of a new subcutaneous C1-inhibitor concentrate for hereditary angioedema.
        Nurs Open. 2018; 6: 126-135https://doi.org/10.1002/nop2.194
        • Li H.H.
        Self-administered C1 esterase inhibitor concentrates for the management of hereditary angioedema: usability and patient acceptance.
        Patient Prefer Adherence. 2016; 10: 1727-1737https://doi.org/10.2147/PPA.S86379
        • Kuhlen J.
        • Guyer A.
        • Morphew T.
        • et al.
        Assessment of home infusion program for treating nonlaryngeal hereditary angioedema attacks.
        Ann Allergy Asthma Immunol. 2014; 112: 471-472https://doi.org/10.1016/j.anai.2014.02.004
        • Gompels M.M.
        • Lock R.J.
        • Abinun M.
        • et al.
        C1 inhibitor deficiency: consensus document.
        Clin Exp Immunol. 2005; 139: 379-394https://doi.org/10.1111/j.1365-2249.2005.02726.x
        • Tuong L.A.
        • Olivieri K.
        • Craig T.J.
        Barriers to self-administered therapy for hereditary angioedema.
        Allergy Asthma Proc. 2014; 35: 250-254https://doi.org/10.2500/aap.2014.35.3753

      Biography

      Kristin Epland, MSP, FNP-C, Advancements in Allergy and Asthma Care, Minnetonka, MN, and can be contacted at [email protected]

      Biography

      Melanie Wayne, MSN, FNP-BC, Oregon Allergy Associates, Eugene, OR.

      Biography

      Heather Pein, PA-C, IMMUNOe Research, Centennial, CO. Kristin Epland is a nurse consultant with Takeda.